These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23956256)

  • 21. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.
    Vandecasteele SJ; De Vriese AS; Tacconelli E
    J Antimicrob Chemother; 2013 Apr; 68(4):743-8. PubMed ID: 23249839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled trial of a vancomycin loading dose in children.
    Demirjian A; Finkelstein Y; Nava-Ocampo A; Arnold A; Jones S; Monuteaux M; Sandora TJ; Patterson A; Harper MB
    Pediatr Infect Dis J; 2013 Nov; 32(11):1217-23. PubMed ID: 23817340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak MJ; Lomaestro BM; Rotschafer JC; Moellering RC; Craig WA; Billeter M; Dalovisio JR; Levine DP
    Pharmacotherapy; 2009 Nov; 29(11):1275-9. PubMed ID: 19873687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
    Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
    Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic monitoring of vancomycin in routine clinical practice].
    Kacířová I; Grundmann M
    Vnitr Lek; 2014 Oct; 60(10):846-51. PubMed ID: 25382007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
    Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
    Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the vancomycin 24-h area under the concentration-time curve (AUC
    Issaranggoon Na Ayuthaya S; Katip W; Oberdorfer P; Lucksiri A
    Int J Infect Dis; 2020 Mar; 92():151-159. PubMed ID: 31935538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Empiric vancomycin dosing in neonates: relationship between initial dose and 24 h area under the curve/minimum inhibitory concentration ratio].
    Klahn A P; Martínez B JP; Sandoval C A
    Rev Chilena Infectol; 2020 Apr; 37(2):99-105. PubMed ID: 32730473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC; Chan JD; Lynch JB; Dellit TH
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized dosing of vancomycin in geriatric patients.
    Suchánková H; Lečbychová K; Strojil J; Fürst T
    Epidemiol Mikrobiol Imunol; 2020; 69(4):172-180. PubMed ID: 33445941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin: we can't get there from here.
    Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
    Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.
    Stockmann C; Roberts JK; Yu T; Constance JE; Knibbe CA; Spigarelli MG; Sherwin CM
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1371-88. PubMed ID: 25301231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.